Emerging Infectious Disease ISSN: 1080-6059

Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human Isolates

Jørgen Engberg*

, Frank M. Aarestrup†, Diane E. Taylor‡, Peter Gerner-Smidt*, and Irving Nachamkin§

Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Frank Aarestrup, Danish Veterinary Laboratory, Copenhagen, Denmark; ‡Diane E. Taylor, University of Alberta, Edmonton, Alberta, Canada; §Irving Nachamkin, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Main Article

Figure 2

Trends for quinolone resistance rates (in percentages) among Campylobacter coli and C. jejuni combined from human sources around the world. The bars represent both nalidixic acid and fluoroquinolone resistance and are based on mean values of resistance from numerous reports (9,17,24,27,39,43,56-58,61-64,72-75,78,88, plus pers. comm. from Feirel G and Rautelin H, and unpub. data from Nachamkin I.).

Figure 2. Trends for quinolone resistance rates (in percentages) among Campylobacter coli and C. jejuni combined from human sources around the world. The bars represent both nalidixic acid and fluoroquinolone resistance and are based on mean values of resistance from numerous reports (9,17,24,27,39,43,56-58,61-64,72-75,78,88, plus pers. comm. from Feirel G and Rautelin H, and unpub. data from Nachamkin I.).

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.